4574.Tライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (26 4月 2024 @ 15:15):

Stats
本日の出来高	99 000.00
平均出来高	488 822
時価総額	17.40B
EPS	¥0 ( 2024-02-08 )
次の収益日	( ¥0 ) 2024-05-09
Last Dividend	¥13.00 ( 2021-12-29 )
Next Dividend	¥0 ( N/A )
P/E	-4.55
ATR14	¥0.925 (0.27%)

ボリューム相関

長: -0.05 (neutral)

短: 0.00 (neutral)

Signal:(57.935) Neutral

Taiko Pharmaceutical 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Taiko Pharmaceutical 相関 - 通貨/商品

-0.63
( weak negative )

-0.28
( neutral )

0.08
( neutral )

-0.46
( neutral )

0.11
( neutral )

0.32
( neutral )

Taiko Pharmaceutical 財務諸表

Annual	2022
収益:	¥5.04B
総利益:	¥1.08B (21.41 %)
EPS:	¥-112.24

FY	2022
収益:	¥5.04B
総利益:	¥1.08B (21.41 %)
EPS:	¥-112.24

FY	2021
収益:	¥10.72B
総利益:	¥2.75B (25.63 %)
EPS:	¥-91.46

FY	2020
収益:	¥17.68B
総利益:	¥12.42B (70.24 %)
EPS:	¥89.18

Financial Reports:

No articles found.

Taiko Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Taiko Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0.484 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	¥0.556	2009-03-26
Last Dividend	¥13.00	2021-12-29
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	¥72.22	--
Avg. Dividend % Per Year	0.00%	--
Score	1.18	--
Div. Sustainability Score	0.484
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2025-02-18)

¥0 Estimate 0.00 %

Dividend Stability

0.06 Very Bad

Dividend Score

1.18

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8136.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
7483.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6707.T	Ex Dividend Knight	2023-09-28	Annually	0.00%
6058.T	Ex Dividend Junior	2024-02-28	Sporadic	0.00%
4733.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3981.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
3186.T	Ex Dividend Junior	2023-11-29	Annually	0.00%
2180.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
9052.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
7942.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.375	1.500	-7.50	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.144	1.200	-4.80	-5.76	[0 - 0.3]
returnOnEquityTTM	-0.261	1.500	-4.01	-6.02	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.19	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.54	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.719	1.500	1.560	2.34	[0.2 - 2]
debtRatioTTM	0.188	-1.500	6.86	-10.00	[0 - 0.6]
interestCoverageTTM	-85.89	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	0	2.00	0	0	[0 - 30]
freeCashFlowPerShareTTM	0	2.00	0	0	[0 - 20]
debtEquityRatioTTM	0.305	-1.500	8.78	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.394	1.000	6.76	6.76	[0.2 - 0.8]
operatingProfitMarginTTM	-0.127	1.000	-4.55	-4.55	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.384	0.800	-0.775	-0.620	[0.5 - 2]
Total Score				0.484

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-6.82	1.000	-0.790	0	[1 - 100]
returnOnEquityTTM	-0.261	2.50	-2.58	-6.02	[0.1 - 1.5]
freeCashFlowPerShareTTM	0	2.00	0	0	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0	2.00	0	0	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.124	1.500	-4.16	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.598

Taiko Pharmaceutical

Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF. It also manufactures and sells sanitation control products under the Cleverin brand name to wholesalers, as well as Cleverin generator, a machine that emits low concentrations of chlorine dioxide gas; and supplies products using the patented Cleverin technology through OEM agreements and products developed jointly with other companies. It exports its products to the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was incorporated in 1946 and is headquartered in Osaka, Japan.`